Related Experiment Video
Updated: Jul 26, 2026
13:36
Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
10.7K
A Replicating Single-Cycle Adenovirus Vaccine Effective against Clostridium difficile
William E Matchett1, Stephanie Anguiano-Zarate2, Goda Baddage Rakitha Malewana3
1Virology and Gene Therapy (VGT) Graduate Program, Mayo Clinic, Rochester, MN 55905, USA.
Vaccines
|August 27, 2020
Summary
A novel vaccine targeting Clostridium difficile toxins A and B demonstrated long-lasting protection in mice and hamsters. This single-cycle adenovirus vaccine offers a promising strategy against C. difficile infections and recurrence.
Area of Science:
- Microbiology
- Immunology
- Vaccinology
Background:
- Clostridium difficile causes severe infections and deaths, with significant healthcare costs.
- Current treatments are limited, highlighting the need for effective prevention strategies.
- Humoral immunity against C. difficile toxins A (TcdA) and B (TcdB) is crucial for protection.
Purpose of the Study:
- To develop and evaluate a novel single-cycle adenovirus (SC-Ad) vaccine against C. difficile.
- To assess the vaccine's ability to induce sustained toxin-binding and neutralizing antibodies.
- To determine the vaccine's protective efficacy against C. difficile challenge in animal models.
Main Methods:
- Development of an SC-Ad vaccine expressing receptor-binding domains of TcdA and TcdB.
- Single immunization of mice and Syrian hamsters with the SC-Ad vaccine.
- Measurement of toxin-binding and neutralizing antibody responses over time.
- Assessment of protection against lethal C. difficile toxin and spore challenge.
Main Results:
- A single immunization in mice induced sustained toxin-binding antibody responses for up to 38 weeks.
- Immunized hamsters showed increasing toxin-neutralizing antibodies for over 36 weeks.
- Complete protection against lethal C. difficile BI/NAP1/027 spore challenge was observed 45 weeks post-immunization.
Conclusions:
- The novel SC-Ad vaccine elicits durable and potent immune responses against C. difficile toxins.
- Single immunization provides long-term protection against C. difficile infection and recurrence in preclinical models.
- This vaccine candidate holds potential for human use in preventing C. difficile-associated disease.
